- Traditional Chinese Medicine (TCM), offering herbal and compound-based formulations for managing viral infections, is increasingly recognized as a vital component of integrated healthcare strategies in both hospital and home settings due to its holistic approach, stage-specific treatment capabilities, and compatibility with conventional therapies.
- The escalating demand for TCM in COVID-19 treatment is primarily fueled by its growing inclusion in national treatment guidelines, increased patient awareness of natural therapies, and a rising preference for multi-targeted, immune-boosting solutions.
- Asia-Pacific dominates the Traditional Chinese Medicine treatment market with the largest revenue share in 2025, characterized by strong cultural acceptance, government-supported research initiatives, and a well-established TCM infrastructure, with China experiencing substantial growth in the production and global export of key formulations such as Jinhua Qinggan and Lianhua Qingwen, driven by innovations in formulation technology and pandemic preparedness programs.
- North America is expected to be the fastest growing region in the Traditional Chinese Medicine treatment market during the forecast period due to increasing interest in alternative medicine, clinical trial collaborations, and growing integration of TCM with conventional care models.
- Parenteral dosage segment is expected to dominate the TCM treatment market with a market share in 2025, driven by its rapid therapeutic onset, suitability for critical stage interventions, and increasing hospital-based administration of injectable compounds like Xiyanping and Xuebijing.
